The core problem the authors confront is one of specificity. CRISPR-Cas9 can, in principle, rewrite the genome with nucleotide-level precision, disabling oncogenic drivers, restoring tumor suppressor pathways, or reprogramming regulatory noncoding elements. In practice, however, the Cas9 protein and its guide RNA are large, charged biological molecules that do not cross cell membranes on their own, degrade rapidly in the bloodstream, and can trigger off-target edits when they reach the wrong cells. Current viral vectors such as adeno-associated virus, or AAV, offer efficient delivery but raise concerns about insertional mutagenesis, limited cargo capacity, immunogenicity, and the sheer difficulty of restricting their tropism to cancer cells alone. Nonviral alternatives have historically suffered from low efficiency. The review positions aptamer-mediated delivery as a way out of this impasse.

Aptamers are selected through an iterative laboratory process known as SELEX, systematic evolution of ligands by exponential enrichment, which screens enormous random-sequence libraries for strands that bind a chosen target with high affinity. Unlike antibodies, aptamers are chemically synthesized, minimally immunogenic, small enough to penetrate dense tumor tissue, and can be modified at will with fluorescent tags, linker chemistries, or therapeutic payloads. The review catalogs aptamers directed against a who’s-who of tumor-associated surface markers: epithelial cell adhesion molecule (EpCAM) overexpressed on many carcinomas, epidermal growth factor receptor (EGFR) in lung and colon cancers, human epidermal growth factor receptor 2 (HER2) in breast cancer, prostate-specific membrane antigen (PSMA) in prostate cancer, nucleolin and protein tyrosine kinase 7 (PTK7) on a range of malignant cells, and the transferrin receptor, which is abundant on the blood-brain barrier and on glioblastoma cells. Each of these ligands can, in principle, be conjugated to a nanocarrier carrying Cas9 ribonucleoprotein complexes or plasmid DNA, converting a systemically administered particle into a homing missile for tumor cells.

One of the most technically interesting contributions of the review is its emphasis on structure-guided molecular docking as a design tool. Rather than relying purely on trial and error, the authors describe how computational docking and molecular dynamics simulations can predict the binding energetics of an aptamer-receptor pair before any wet-lab work begins. By modeling the three-dimensional folds that aptamers adopt, researchers can rationally introduce mutations that strengthen the binding interface, improve discrimination between the tumor target and closely related proteins on healthy cells, and truncate aptamers to the minimal binding domain, reducing manufacturing cost and immunogenic potential. This computational-first workflow, the review argues, is transforming aptamer engineering from an artisanal craft into a predictable engineering discipline.

Getting the particle bound to the cell surface, however, is only the first hurdle. The review devotes substantial attention to what happens next: receptor-mediated endocytosis, the process by which the cell swallows the bound particle into an endosome, followed by the equally critical step of endosomal escape. Most nanoparticles that successfully enter cells end up trapped and degraded in lysosomes, which is why delivery efficiency is often measured in frustratingly low single digits. The authors survey the escape strategies now being built into aptamer-functionalized carriers, including proton-sponge effects from polyethylenimine-based formulations, pH-responsive membrane-disruptive polymers, and fusogenic lipids that destabilize the endosomal membrane as its interior acidifies. Understanding which endocytic pathway, clathrin-mediated, caveolae-mediated, or macropinocytosis, a given aptamer-receptor pair exploits allows researchers to co-opt the cell’s own trafficking machinery and steer the cargo toward the cytosol and ultimately the nucleus, where Cas9 must arrive to do its work.

The third pillar of the framework is nanocarrier engineering, and here the review offers a sweeping comparison of the leading platforms. Lipid nanoparticles, validated clinically by the mRNA vaccine campaigns, remain the front-runner, with refinements in PEG-lipid architectures, such as cleavable DSPE-PEG anchors and optimized PEG densities, improving colloidal stability while avoiding accelerated blood clearance on repeat dosing. Polymeric carriers built from PLGA and PAMAM dendrimers offer controlled release profiles, while inorganic platforms, including mesoporous silica nanoparticles and gold nanoparticles, provide stimulus-responsive gates that open in the acidic tumor microenvironment. Extracellular vesicles, the natural nanoshuttles secreted by cells themselves, offer innate biocompatibility and the ability to cross biological barriers, and hybrid viral-nonviral platforms attempt to marry viral entry efficiency with the safety and tunability of synthetic materials.

What distinguishes this review from earlier surveys of CRISPR delivery is its insistence that these three elements, targeting ligand, trafficking route, and carrier chemistry, must be co-optimized rather than designed in isolation. A particle decorated with a superb aptamer but lacking endosomal escape capability will never deliver an active nuclease. A carrier with perfect intracellular performance but rapid serum clearance will never reach the tumor. The authors highlight how the dense, fibrotic extracellular matrix of many tumors physically blocks nanoparticle penetration, and how aptamer-mediated binding to receptors expressed deep within tumor spheroids can enhance accumulation in poorly perfused regions. They also discuss spatiotemporally controlled editing, in which carriers release their cargo only in response to tumor-specific cues such as hypoxia, low pH, or externally applied light or ultrasound, limiting genome modification to the tumor microenvironment.

The potential clinical applications span the full breadth of oncology. Targeted knockout of oncogenic drivers such as mutant EGFR in non-small cell lung cancer, disruption of the Wnt pathway via adenomatous polyposis coli-related targets in colorectal cancer, editing of immune checkpoints such as PD-1 to unleash antitumor immunity, and correction of tumor suppressor defects through homology-directed repair are all within the conceptual scope of aptamer-guided delivery. The authors also note synergies with established modalities: aptamer-targeted carriers could deliver Cas9 engineered to knock out drug-resistance genes alongside conventional chemotherapy, or complement CAR T-cell therapy by editing immune cells ex vivo with higher efficiency and lower toxicity than viral transduction.

The authors are admirably candid about the obstacles that remain. In vivo stability of both aptamers and Cas9 cargos in the face of nucleases and proteases, the scalability and reproducibility of GMP-grade nanomanufacturing, the persistent specter of off-target double-strand breaks, and the dearth of rigorous long-term preclinical and clinical validation all stand between the current state of the art and routine bedside use. Aptamer affinity measured in a culture dish does not always translate to four-hour circulation in human plasma, and off-target editing in non-tumor tissue remains the field’s most serious safety concern. Yet the trajectory is unmistakable. By integrating rational aptamer design, mechanistic understanding of intracellular trafficking, and increasingly sophisticated nanocarrier engineering, the field is assembling the complete delivery toolkit that precision genome editing oncology has been waiting for. If the remaining challenges can be met, aptamer-guided CRISPR-Cas9 systems could move genome surgery from the laboratory bench to the cancer clinic, offering patients therapies that edit the disease at its genetic source while sparing healthy tissue entirely.

Subject of Research: Aptamer-mediated CRISPR-Cas9 delivery systems for targeted cancer genome editing

Article Title: Aptamer-mediated CRISPR-Cas9 delivery for precision oncology: integrating molecular targeting, intracellular trafficking, and nanocarrier engineering

Article References: Saffari Natanzi, A., Ahmadi, E., Shahraki, S., Eslamian Koupaei, A., & Haddad Kashani, H. (2026). Aptamer-mediated CRISPR-Cas9 delivery for precision oncology: integrating molecular targeting, intracellular trafficking, and nanocarrier engineering. Advanced Composites and Hybrid Materials. https://doi.org/10.1007/s42114-026-02049-2

Image Credits: AI Generated

DOI: 10.1007/s42114-026-02049-2

Keywords: aptamers, CRISPR-Cas9, precision oncology, targeted delivery, nanocarriers, lipid nanoparticles, gene editing, endosomal escape, molecular docking, SELEX, tumor microenvironment, cancer therapy

The work addresses a gap that has shaped the trajectory of genome engineering for more than a decade. Since the advent of programmable nucleases, researchers have been able to direct double-strand breaks to almost any chosen sequence, and cellular repair machinery can sometimes stitch in a new DNA cassette at the break site. But that approach leans on the cell’s own repair pathways, which are error-prone, unpredictable and often disabling to the very sequences scientists want to insert. Broken DNA is dangerous DNA, and cells treat integration events as injuries to be patched rather than as opportunities for precise reconstruction.

Prime editing, first described in 2019, took a fundamentally different route. Rather than cutting both strands of the DNA double helix, a prime editor pairs a Cas9 nickase — an engineered enzyme that cuts only one strand — with an engineered reverse transcriptase. The editing instructions are carried on a prime editing guide RNA, or pegRNA, which both locates the target site and encodes the new genetic information the reverse transcriptase should write into the nicked strand. Because the process avoids double-strand breaks and does not require an additional donor DNA template supplied in bulk, prime editing has proven remarkably clean for small substitutions, insertions and deletions.

Where prime editing has historically faltered, however, is scale. The reverse transcriptase copies a sequence encoded within the pegRNA itself, and practical constraints on RNA length, delivery and synthesis efficiency have limited the size of the DNA payload that a single prime-editing event can install. For applications in which a functional gene, a large regulatory element or a multi-kilobase cassette must be placed at a defined genomic address, the technology’s ceiling has been a persistent frustration. Complementary systems — including CRISPR-associated transposases and integrase-based platforms — can move larger cargoes, but they typically bring their own constraints on target-site selection, orientation and cargo compatibility.

The new study, led by researchers working at the interface of protein engineering and genome technology, tackles the size problem by rethinking how the donor DNA participates in the reaction. In the reported strategy, termed donor-directed annealing, the genetic cargo is carried on a separate donor molecule rather than being encoded within the pegRNA. The prime editor still performs its characteristic task of opening the target site and synthesizing an exposed stretch of new DNA on the nicked strand, but that newly synthesized sequence is designed to serve as a molecular landing pad. Once exposed, it is complementary to sequences at the end of the donor fragment, and the two single-stranded regions find each other and anneal, drawing the donor cargo into the editing site.

The elegance of the design lies in what happens next. Cellular DNA repair enzymes process the annealed intermediate, ligating the donor fragment into the genome through the natural resolution of the flap-like structure that the prime editor has created. Because the specificity of the event is dictated by sequence complementarity between the editor-generated overhang and the donor terminus, the cell is never asked to recognize a double-strand break or to improvise an end-joining reaction. The authors report that this mechanism allows fragments substantially larger than the payloads accessible to conventional prime editing to be incorporated at defined loci, with precision determined largely by the programmed overlap rather than by stochastic cellular repair.

From a biochemical standpoint, donor-directed annealing converts what has been an intramolecular copying reaction into a hybridization-guided assembly step. Conventional prime editing is, in essence, a controlled form of DNA synthesis: the pegRNA templates every base that the reverse transcriptase installs. The new method retains that templated synthesis for a short anchoring sequence but delegates the bulk of the payload to a separate donor, which can be produced synthetically or by standard cloning at lengths far beyond what a pegRNA can encode. The trade-off is that the donor and the pegRNA must be co-delivered and their sequences coordinated, but the payoff is a system in which cargo size is no longer bound to the physical limits of the guide RNA.

The practical implications extend across both research and therapeutic arenas. In basic biology, the ability to drop large regulatory modules, reporter constructs or engineered gene circuits into precise genomic contexts would simplify experiments that currently require laborious screening of random integration events. In medicine, many inherited disorders are caused by mutations in genes that are too large, too structurally complex or too mutationally diverse to be addressed base by base. Delivering a corrected copy of a gene, or a functional cDNA, into its native locus under the control of endogenous regulatory elements — rather than scattering it randomly through the genome as viral vector gene therapy does — remains the aspirational gold standard, and integration strategies of this kind are among the most credible paths toward it.

The reported system also speaks to a recurring theme in the genome-editing literature: the value of avoiding double-strand breaks altogether. Studies across multiple cell types have associated double-strand-break-based editing with p53 activation, chromosomal rearrangements and large unintended deletions, concerns that are particularly acute for ex vivo cell therapies and in vivo applications alike. By building integration on a nicking enzyme and sequence-programmed annealing rather than on blunt-ended break repair, the approach aligns with the field’s broader movement toward editing chemistries that leave the genome’s integrity machinery largely undisturbed.

As with any genome-engineering advance, several questions will shape how the technique matures. The efficiency of integration across different genomic loci, cell types and species will need systematic mapping; cargo lengths will have practical ceilings set by delivery vehicles rather than by chemistry; and off-target activity — a concern for any nuclease-fusion system — will require careful characterization at both the sequence and chromosomal level. The study’s authors report encouraging precision at the sites they examined, and the strategy’s dependence on designed sequence complementarity offers a built-in specificity checkpoint that many integration methods lack. Independent replication and optimization in therapeutically relevant primary cells will be the next milestones.

What the work illustrates most clearly is how quickly the conceptual boundaries of genome editing continue to move. In barely a decade, the field has progressed from cutting DNA at chosen addresses, to rewriting individual letters of the genetic code, to contemplating the programmed installation of whole functional modules at will. Donor-directed annealing extends prime editing’s core strengths — precision, minimized DNA damage and programmability — into a size regime that those strengths had not previously reached. If the method’s efficiency and reliability hold up as it is tested more broadly, large-fragment insertion could shift from a heroic, low-yield exercise to a routine operation in the genome engineer’s toolkit, with consequences for drug discovery, synthetic biology and, ultimately, the treatment of diseases that small edits alone cannot fix.

Subject of Research: Precise integration of large DNA fragments into genomic target sites using prime editing with donor-directed annealing

Article Title: Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing

Article References: Jung, H., Jeong, B., Kim, Y.-W., Jung, C., Lee, S., Uhm, H., Kim, H., Oh, Y. E., Park, Y., Lee, Y., Kang, M., Im, H. W., Kim, D., Lee, S., Kim, Y., Choi, K., & Bae, S. (2026). Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03301-2

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03301-2

Keywords: prime editing, genome editing, CRISPR, gene therapy, DNA integration, pegRNA, reverse transcriptase, Cas9 nickase, large DNA fragments, donor-directed annealing, biotechnology, genetic engineering

The structure shows that the answer lies in a strategy biologists describe as structural mimicry. When Cas12a takes up its DNA guide, the complex does not merely carry the guide as a passive address label. Instead, the enzyme and the guide together fold into a shape that persuades the incoming RNA target that it has met a compatible partner. The guide strand and parts of the protein scaffold arrange themselves into a geometry that resembles the duplex the RNA would normally form, allowing the RNA to thread into the complex and pair with the guide as though it were engaging a conventional nucleic-acid partner. In other words, the system speaks RNA’s language while carrying DNA’s script.

To appreciate why this matters, it helps to recall what makes Cas12a unusual among CRISPR nucleases. Unlike Cas9, which requires two separate RNA molecules to form its active guide and creates blunt cuts in DNA, Cas12a needs only a single short RNA guide, recognizes a distinct class of protospacer-adjacent motifs, and cuts DNA in a staggered fashion that leaves overhanging ends prized by genome engineers. Cas12a also belongs to the subset of CRISPR effectors whose natural guide can be encoded in DNA, and once activated by a matching target it unleashes indiscriminate collateral cutting of nearby single-stranded nucleic acids, a behavior that underpins a growing portfolio of diagnostic tests. Every one of those applications depends on the same underlying event: the correct pairing of the guide with the intended target inside the enzyme’s grip.

The newly determined structure captures that event in remarkable detail. Acidaminococcus sp. Cas12a is seen cradling the pseudo-DNA guide in its central channel, with the guide’s seed region, the stretch of sequence that makes first contact with a prospective target, held in an ordered conformation that pre-organizes it for recognition. When the RNA target arrives, it threads through the complex and pairs with the guide, and the resulting hybrid duplex sits within a pocket lined with positively charged residues that stabilize the intertwined strands. Around this core, the protein domains that had been clamped open in the absence of a target rearrange into a catalytically competent architecture, snapping the enzyme into its cutting mode. The structure therefore presents both the resting and the engaged states of recognition in a single frozen moment.

What stands out most is how the pseudo-DNA guide participates in the deception. In related systems, RNA guides form extensive pairing interactions with the protein that keep them in the correct register. Here, the DNA guide relies on a hybrid strategy: parts of it mimic the conformation that an RNA guide would adopt, while the protein supplies compensatory contacts that read DNA’s distinctive chemical features, including the absence of the 2′-hydroxyl groups that decorate RNA. The researchers show that this arrangement allows the complex to present a target-binding surface that is effectively indistinguishable, in shape and charge distribution, from the surface presented by RNA-guided relatives. The RNA target, encountering this surface, binds and pairs with a partner that is chemically DNA but structurally fluent in RNA.

This mimicry extends to the catalytic heart of the enzyme. Cas12a’s nuclease activity depends on the RuvC domain, a processing module shared with other members of the CRISPR-Cas superfamily. In the new structure, the RuvC active site is positioned relative to the guide-target duplex in a way that mirrors its placement in RNA-guided complexes, confirming that the downstream cutting machinery does not care whether the guide is made of DNA or RNA. What matters is the geometry of the duplex delivered to it. By achieving that geometry through mimicry, Acidaminococcus Cas12a solves a chemical problem that would otherwise seem insurmountable: a DNA guide cannot form the same Watson-Crick interactions with the protein that RNA guides use, yet it must produce the same structural outcome.

The biological logic of such a system is thought to trace back to the evolutionary history of CRISPR effectors. Many researchers believe that the ancestral defense machines were RNA-guided, targeting the genetic material of viruses directly, and that DNA-guided variants emerged as immune systems shifted toward attacking DNA genomes. The new structure offers a snapshot of how that transition could be engineered by evolution without redesigning the whole enzyme: keep the recognition and cutting apparatus intact, and evolve the guide-binding channel so that a DNA guide is chaperoned into an RNA-like conformation. Structural mimicry, in this view, is not a curiosity but an economical evolutionary patch, and the pseudo-DNA guide captured in the structure may itself represent an intermediate stage in that ongoing molecular negotiation.

For technologists, the structure arrives as something closer to a blueprint than a curiosity. Genome editing with Cas12a is already routine in laboratories, and its single-guide simplicity, compact size and staggered cuts have made it a favorite for applications ranging from agriculture to therapeutic development. But rational engineering of Cas12a, whether to alter its motif preferences, improve its specificity, retune its collateral activity for diagnostics, or expand the range of sequences it can target, has been constrained by incomplete knowledge of how the DNA guide and the RNA target actually sit inside the enzyme. By showing precisely which residues cradle the guide, which contacts read the target, and which conformational changes license cutting, the structure gives engineers a map of the interaction surfaces they can mutate deliberately rather than by trial and error.

The diagnostic implications may be especially immediate. Cas12a-based assays, which detect pathogens or disease sequences by coupling target recognition to a fluorescent collateral-cutting reaction, depend critically on the sensitivity and specificity of the initial guide-target pairing. Understanding how a DNA guide presents itself to an RNA target, and how mismatches are sensed within the duplex, opens the door to designing guides and protein variants that discriminate more sharply between true targets and near matches, reducing false positives that have complicated real-world deployment. It also suggests routes to building entirely new guide chemistries: if the enzyme tolerates a pseudo-DNA guide, other modified nucleic acids might be accommodated within the same channel, each tuned for stability or detection chemistry.

Therapeutic engineering stands to gain as well. Cas12a’s relatively compact size makes it deliverable in gene-therapy vehicles that struggle to carry bulkier nucleases, and a validated atomic model of its target-recognition state enables computational screening of variants before any test tube is touched. Researchers seeking to minimize off-target editing can now ask structural questions that were previously unanswerable: which protein contacts relax the specificity of pairing, and which lock the seed region into a demanding standard. The same map can guide the design of anti-CRISPR or regulatory proteins that jam the recognition interface, offering a way to switch editing on or off in living systems.

Like any single structure, the model of Acidaminococcus Cas12a bound to a pseudo-DNA guide and RNA target is one frame in what is certainly a dynamic process. The enzyme undergoes further rearrangements during target cleavage and product release that remain to be visualized, and different Cas12a homologs may solve the DNA-guided recognition problem with variations on the theme revealed here. But the central finding is unlikely to change: the division between RNA-guided and DNA-guided CRISPR systems is thinner than it appears. At the level of three-dimensional architecture, the two families speak the same structural language, and one has been caught in the act of translation. That translation, now legible at near-atomic resolution, is precisely the kind of insight from which the next generation of CRISPR tools will be built.

Subject of Research: Cryo-EM structure of Acidaminococcus sp. Cas12a bound to a pseudo-DNA guide and RNA target

Article Title: Architecture of a DNA-guided Cas12a

Article References: Architecture of a DNA-guided Cas12a. (n.d.). https://doi.org/10.1038/s41594-026-01894-5

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01894-5

Keywords: Cas12a, CRISPR, cryo-electron microscopy, structural mimicry, DNA-guided recognition, RNA target, gene editing, Acidaminococcus, nuclease, molecular structure, biotechnology, diagnostics

The study, led by Sophie van Baalen, Thomas Verra and Michelle Habets of the Rathenau Instituut in the Netherlands, together with colleagues at Wageningen University and Erasmus MC, conducted nineteen semi-structured interviews with scientists working in academia and industry between September 2023 and January 2024. Fifteen of the respondents were academic researchers and four worked for commercial companies, with expertise spanning biomedical research, plant science and microbiology. Using snowball sampling and thematic analysis with Atlas.ti software, the team captured the views of researchers across ten European countries and one respondent from the United States, continuing recruitment until no new themes emerged from the transcripts.

The technical logic behind epigenetic editing explains much of its appeal. Unlike CRISPR-Cas9 gene editing, which slices both strands of the DNA double helix to alter the genetic sequence, epigenetic editing tools such as CRISPR-dCas9 and zinc finger proteins bind to specific DNA sequences without cutting them. Instead of changing the letters of the genetic code, they attach or remove chemical marks on the DNA and its associated proteins, dialing gene activity up or down. Because no DNA breaks are introduced, researchers assume the risk of genomic instability is dramatically reduced. Off-target effects, a persistent worry in gene editing, are viewed as less dangerous in the epigenetic version because misplaced edits do not coincide with strand cuts and may fade over time as the cell’s own machinery reverses the marks.

Respondents also described epigenetic editing as fundamentally more subtle than gene editing. Where gene editing acts like a binary switch, introducing or eliminating genetic functions outright, epigenetic editing was compared to a thermostat that fine-tunes the volume of gene expression. Because cells naturally modify their epigenome constantly as part of ordinary biology, scientists framed the technique as working with, rather than against, the cell’s native processes. Several researchers contrasted this precision favorably with epigenetic drugs, a class of therapeutics that targets epigenetic enzymes broadly and is notorious for lacking specificity. One interviewee emphasized the absence of the translocation problems and genetic instability that plague strand-cutting technologies, noting that unlike base editing, prime editing or conventional gene editing, epigenetic editing never cuts the DNA at all.

Yet the same scientists who endorsed this dominant vision simultaneously questioned its foundations, sometimes without being prompted. The reservations clustered around three scientific uncertainties: reversibility, heritability and complexity. On reversibility, researchers acknowledged that while a limited number of studies have shown epigenetic edits can be reversed or remain stable, it is currently impossible to predict whether an edit at a particular genomic location will persist or vanish, and for how long. This creates an awkward paradox, because the stability needed for durable medical treatments and agricultural applications is exactly what undermines the promised safety net of reversibility. As one respondent explained, scientists do not really know what makes some epigenetic modifications stick around for years while others disappear within days, and following patients long enough to find out would require decades-long cohort studies.

Heritability raised equally thorny questions. For epigenetic editing to work in medicine or agriculture, edits must survive cell division, a property called mitotic heritability, and respondents disagreed about whether they reliably do. The possibility of intergenerational and transgenerational inheritance troubled some biomedical researchers, who worried about unintended effects on the offspring of treated patients, while some plant scientists actually counted on epigenetic edits fading out over generations, reasoning that edited crops escaping into the wild would lose their modifications naturally. The third concern, complexity, struck at the heart of the technology’s predictability. Gene expression is governed by intertwined networks in which cause and effect are not linear; altering an epigenetic mark at one location can trigger cascades of unforeseen changes across hundreds of other genes, especially when the three-dimensional folding of DNA and crosstalk between cells enter the picture. One respondent noted that outside of genomic imprinting, they could not think of a single epigenetic network that is well enough characterized to guarantee a clear therapeutic output.

Despite these doubts, three distinct visions of the technology’s medical future emerged among respondents. The prevailing outlook was hopeful but modest: epigenetic editing could eventually treat cancers driven by epigenetic changes, boost the effectiveness of CAR-T immunotherapies, and address rare diseases caused by epimutations, with early clinical trials restricted to patients who have exhausted all other options. Some argued that medicine routinely advances without fully understanding a drug’s mechanism, so demanding perfection before testing would mean never developing the therapy at all. At the cautious extreme, a minority, particularly basic researchers outside translational work, warned that epigenetic editing could prove less safe than gene editing, since introducing epimutations might reactivate dormant transposons or derail cellular identity in ways scientists can no longer control once edited cells are inside the body. At the opposite pole, a small group envisioned a medical revolution in which epigenetic editors retune multiple genes simultaneously, potentially transforming treatment of autoimmune disease, diabetes, Alzheimer’s and even aging, with speculative applications ranging from skin-rejuvenating creams to cures for HIV and chronic hepatitis B.

The agricultural picture diverged sharply. Plant scientists interviewed for the study did not consider epigenetic editing a commercially viable breeding technology, largely because seed companies require traits that remain stable across generations and environmental conditions, from the controlled greenhouse to the unpredictable open field. Backcrossing can eliminate unwanted off-target changes in plants, removing one of epigenetic editing’s main selling points. Still, respondents sketched hypothetical applications that could eventually prove transformative, such as plant varieties that switch on disease-resistance genes only when a pathogen is actually present, or epigenetic control of flowering, which could dramatically shorten breeding cycles for seed production.

The study’s timing makes its findings particularly pointed. While most respondents questioned whether the technology is ready for real-world deployment, companies are already racing ahead: OMEGA Therapeutics completed a first-in-human clinical trial using epigenetic editing to suppress the oncogene c-MYC in twenty-four participants before filing for bankruptcy in early 2025, and Tune Therapeutics is currently recruiting patients for a trial of an epigenetic silencing therapy for chronic hepatitis B. The authors highlight a mismatch between the private sector’s focus on common, profitable conditions such as high cholesterol and obesity, exemplified by celebrated preclinical results showing durable cholesterol reduction in mice and primates, and the academic community’s caution. They argue that the dominant safety narrative is performing rhetorical work, positioning epigenetic editing as publicly acceptable in ways that may prove premature, and warn of a hype-disappointment cycle reminiscent of the gene therapy backlash of the 1990s. The researchers call for explicit reflexivity within the field, public engagement and citizen participation in shaping the technology’s future, and urge scientists to clearly articulate what evidence is truly needed before epigenetic applications move toward the clinic, arguing that making these visions explicit allows scientists, policymakers and the public to reflect on, adapt and co-create the trajectory of this emerging technology rather than simply inherit whatever future the loudest promises deliver.

Subject of Research: Scientific visions, expectations and reservations regarding epigenetic editing and its responsible innovation

Article Title: Visions, expectations, and reservations in epigenetic editing: towards responsible innovation

Article References: van Baalen, S., Verra, T., Macnaghten, P., Bunnik, E., & Habets, M. G. (2026). Visions, expectations, and reservations in epigenetic editing: towards responsible innovation. Epigenetics Communications, 6(1), Article 6. https://doi.org/10.1186/s43682-026-00047-5

Image Credits: AI Generated

DOI: 10.1186/s43682-026-00047-5

Keywords: epigenetic editing, epigenome, CRISPR-dCas9, gene expression, responsible innovation, gene editing, biotechnology, clinical trials, plant breeding, science and technology studies, research ethics, public acceptance

The difficulty begins with how conventional CRISPR editing works. The canonical Cas9 nuclease cuts both strands of DNA at a targeted site, and the cell’s repair machinery then patches the wound. That repair is precise only if researchers supply a matching template and the cell uses homology-directed repair, a pathway that operates mainly in dividing cells and is notoriously inefficient. Left to its default machinery, non-homologous end joining, the cell scrambles the junction, producing unpredictable insertions and deletions. At sites cut on both strands, graver outcomes can follow: large deletions, inversions, chromosome rearrangements, and the activation of DNA-damage responses that can select against successfully edited cells. For knocking out a gene, such collateral damage is tolerable. For writing a therapeutic sequence into a defined position, it is disqualifying. Many of the most valuable edits, moreover, are large by nature: whole exons, entire genes, or regulatory modules that can span thousands of bases. Large, precise insertions have therefore been the stubborn frontier of genome editing, achievable mainly with viral vectors, transposases, or site-specific recombinases, each of which carries its own cargo limits, targeting constraints, or safety concerns.

Prime editing, first demonstrated in 2019, offered a gentler alternative. Instead of cutting both strands, a prime editor pairs a nicking form of Cas9 with an engineered reverse transcriptase. Its guide RNA, the prime editing guide RNA or pegRNA, does double duty: it locates the genomic target and carries a short RNA template that the reverse transcriptase copies directly onto the nicked strand. Because the intact complementary strand then guides repair, the method can install substitutions, small insertions, and deletions without a double-strand break. Prime editing has since proved itself for point mutations and compact edits. Writing kilobases of DNA, however, means asking the reverse transcriptase to copy enormously long RNA templates, and the efficiency of that synthesis falls steeply as templates lengthen. Larger inserts have generally demanded workarounds — twin-prime-editing schemes, integrase-based platforms, or engineered transposases — each of which adds enzymes, extra steps, or sequence constraints that limit where and how well the method works.

DoPE’s central insight is to stop asking the editor to synthesize the insert and instead let the insert deliver itself. The method couples a PE2* prime editor with a pair of overhang-complementary prime editing guide RNAs — opegRNAs — and a double-stranded DNA donor whose ends carry short 3′ single-stranded overhangs. Each opegRNA directs the editor to one side of the intended insertion site and encodes an overhang sequence complementary to one end of the donor. As the editor nicks each flanking strand and extends the exposed 3′ ends, the genome itself acquires sticky ends that mirror the donor’s. The matching sequences then anneal like two halves of a zipper, tethering the donor DNA into the gap between the two nicked sites, after which the cell’s own ligation and repair activities seal both junctions and complete the insertion. Precision comes from that complementarity: the donor anneals only where its overhangs find matching genomic sequences, so integration is guided by design rather than left to chance. Because the cargo arrives as pre-made DNA rather than being reverse-transcribed base by base, its length is limited less by the editor’s synthetic capacity than by delivery, which is why the same chemistry accommodates everything from tiny fragments to sequences longer than ten kilobases.

In the new study, the team reports precise insertions reaching 12.5 kilobases, a scale few cut-free methods achieve without enlisting integrases or transposases. Strikingly, the sticky ends that make the system work are short: overhangs of roughly 30 nucleotides proved sufficient to support the full range of inserts, from small fragments to sequences exceeding 10 kilobases. That brevity has practical consequences. The overhang is essentially the only custom sequence the platform needs, so retargeting the system or changing the cargo means redesigning two short guide RNAs and the donor ends rather than re-engineering the editor itself. One opegRNA pair, one editor, and a donor of whatever size the experiment demands — the architecture stays constant whether the cargo is a few bases or an entire gene-sized module. That plug-and-play quality is precisely the behavior that earlier insertion platforms, with their fixed recognition sites and enzyme-specific requirements, have struggled to deliver.

The same design turns out to be library-compatible, and that may prove its most consequential property. Because donors can be pooled, the researchers built collections from synthesized single-stranded oligonucleotides and used a single opegRNA pair to install a saturated library of mutations across a targeted region of EGFP, the gene for a green fluorescent reporter protein. The result was in situ saturation mutagenesis: the targeted stretch of the genome was rewritten with a comprehensive set of variants, resolvable at both amino-acid and single-nucleotide resolution, all generated inside cells in one experiment. Deep mutational scanning, the workhorse technique for measuring how thousands of protein variants behave, usually requires elaborate cloning campaigns to assemble variant libraries before they ever encounter a cell. DoPE compresses that workflow, writing the library directly into the genome in its native context, ready to be sorted and sequenced. For protein engineering, regulatory-element design, and systematic functional genomics, the method offers a route from sequence concept to cellular library without a cloning bottleneck.

The therapeutic proof of concept targeted PRKCSH, a gene whose loss-of-function mutations are linked to autosomal dominant polycystic liver disease, a condition in which fluid-filled cysts progressively enlarge the liver. Rather than correcting each patient’s mutation individually, the team used DoPE to replace mutant exons of PRKCSH — one exon at a time or two exons simultaneously — restoring the correct sequence wholesale. The strategy is mutation-agnostic: because whole exons are swapped for their healthy counterparts, any mutation lying within the replaced segment, whatever its chemical nature, is repaired by the same edit. That property addresses a persistent headache in gene therapy. Many disease genes harbor not one recurring mutation but a sprawl of rare variants scattered across the gene, and designing a bespoke editor for each is impractical. Exon-level replacement offers a single design that can cover many patients, and the study reports that distinct alleles were corrected uniformly in vitro, an early indication that the approach performs consistently across different mutant starting points.

Set against existing large-insertion tools, DoPE occupies a distinctive niche. Adeno-associated viral vectors can ferry genetic cargo but are size-restricted and integrate at random rather than chosen positions. Transposon systems move large fragments but with limited site specificity. Integrase-based platforms combine a prime editor with a serine integrase to install large sequences, and CRISPR-associated transposases target defined sites, but both recruit additional enzymes with their own sequence requirements and insertion preferences. DoPE’s parts list is minimal: one PE2* editor, two opegRNAs, and a synthetic DNA donor. No double-strand break occurs at any point, so the genotoxic hazards associated with cut-based editing — unpredictable indels at the junction, chromosomal scrambling, and DNA-damage signaling — are avoided by design rather than managed after the fact. And because targeting is written into the guide RNAs, any genomic site compatible with prime editing can in principle serve as a landing pad, keeping the method programmable in the same sense that CRISPR itself is.

The caveats are those that attend any new genome-editing platform. The results reported here were obtained in cultured cells, and performance in primary cells, tissues, and whole organisms — where delivering both a large editor and a double-stranded donor DNA is considerably harder — remains to be demonstrated. Efficiency and precision will need to be measured across many genomic contexts and cell types, and the platform’s byproduct profile, including any partial-edit intermediates or mis-annealed donors, will require systematic characterization. Off-target activity, a concern for every CRISPR-derived tool, will need dedicated assessment at scale. Independent replication across laboratories, as with any powerful new technique, will also shape how quickly the field adopts it. None of these open questions diminishes the conceptual advance; they simply mark the distance between an elegant chemistry demonstrated in vitro and a dependable research tool or therapy. The history of prime editing itself suggests a trajectory worth watching: the original system was a proof of principle in 2019 and has since been sharpened through successive rounds of protein and guide-RNA engineering.

If the method’s cell-culture performance carries forward, its implications are broad. Kilobase-scale, DSB-free, site-specific insertion without recombinases would let researchers install entire genes, swap promoters, or build synthetic regulatory circuits at defined loci, and would give gene therapy a candidate strategy for the many disorders caused by scattered mutations across large genes. The library mode, meanwhile, turns the genome itself into the substrate for high-throughput experimentation, potentially accelerating everything from enzyme evolution to the dissection of noncoding DNA elements. Genome editing began as a scalpel — a way to cut a chosen sequence and let the cell cope with the consequences. Prime editing recast it as a pencil, correcting individual letters without breaking the strand. DoPE pushes the metaphor further still: less a pencil than a compositor’s hand, setting whole paragraphs of DNA onto the genome’s page, one designed insert at a time.

Mitochondrial DNA, distinct from the nuclear genome, resides inside the mitochondrion and is inherited maternally. Its mutations contribute not only to a diverse collection of rare genetic diseases but also have implications in cancer progression and age-related cellular decline. Historically, genome editing technologies such as CRISPR-Cas9 revolutionized nuclear DNA manipulation but fell short when applied to mitochondria owing to their impermeable double membranes and the absence of natural RNA import pathways necessary for CRISPR’s function.

The innovative approach developed by the research team circumvents these challenges by deploying a highly specialized tool known as a mitochondrial base editor. This editor, a double-stranded DNA cytosine base editor (DdCBE), enables precise conversion of cytosine to thymine within the mitochondrial genome without necessitating the formation of double-stranded breaks. This subtle yet powerful mechanism ensures minimal genomic disruption, a crucial advantage given the sensitivity of mitochondrial functions.

In rigorous laboratory experiments, the researchers first engineered liver cell organoids to harbor a mutation within their mitochondrial DNA that severely compromises cellular energy production. These patient-derived liver organoids—three-dimensional tissue cultures closely replicating physiological conditions—served as effective models to study the pathophysiology of mitochondrial diseases. Upon application of the DdCBE base editor, they successfully corrected the mutation, demonstrating restoration of mitochondrial function and energy metabolism within these cells.

Moreover, the team extended their strategy to skin cells obtained from a patient diagnosed with Gitelman-like syndrome, a rare mitochondrial disorder characterized by electrolyte imbalances and neuromuscular symptoms. By targeting and repairing a pathogenic variant within these patient-derived cells, the scientists were able to restore key physiological indicators of healthy mitochondrial function. This achievement not only underscores the therapeutic potential of mitochondrial base editors but also highlights their ability to function in diverse cell types affected by mitochondrial diseases.

An essential aspect of translating this technology into clinical settings is the development of safe and efficient delivery systems for the gene editing components. The researchers innovated by delivering the RNA message encapsulating the base editor’s instructions in the form of messenger RNA (mRNA) rather than DNA plasmids, thereby mitigating the risk of genomic integration and genotoxicity. Encapsulation within lipid nanoparticles (LNPs) further enhanced delivery efficiency and reduced cellular toxicity. LNP-mediated mRNA delivery, already lauded for its success in mRNA vaccines, offers a promising vector for targeted mitochondrial therapies.

Equally significant was the high specificity of the editing process. Comprehensive genomic analyses revealed negligible off-target effects within the nuclear genome, alleviating concerns about unintended mutagenesis in the cell’s main genetic repository. While some off-target edits were detected within mitochondrial DNA, these were minimal and can be further mitigated through ongoing optimization. The precision achieved in this study underscores the technical sophistication of mitochondrial base editing, setting a new benchmark in genomic medicine.

The promise of this technique lies not only in its immediate ability to model mitochondrial diseases in vitro but also in its potential as a direct therapeutic intervention. Historically, patients with mitochondrial disorders had limited treatment options, primarily symptomatic management or supportive care. The advent of a tool capable of directly correcting the root genetic causes within mitochondria could transform clinical approaches, possibly leading to cures rather than palliation.

Importantly, this study leveraged clinic-grade techniques and patient-derived organoids, bringing the research closer to clinical application. The use of human cells and organoid models ensures translational relevance and provides a platform for evaluating therapeutic efficacy and safety with unprecedented accuracy. The approach moves the field from theoretical genome editing strategies toward tangible medical innovations.

Despite the promise, challenges remain. Efficient delivery of base editors in vivo—especially to organs predominantly affected by mitochondrial diseases like muscle and brain tissue—requires further refinement. Immune responses, editing efficiency across diverse mitochondrial haplotypes, and long-term effects of editing in post-mitotic cells present hurdles yet to be fully surmounted. Nonetheless, the demonstrated ability to edit mitochondrial DNA with base editors is a monumental leap forward.

The researchers emphasize that their work symbolizes the dawn of a new era in mitochondrial medicine, one where gene editing technologies will finally bridge the long-standing gap presented by mitochondrial genetics. For decades, mitochondrial patients have lagged behind the CRISPR revolution, but innovations such as these offer renewed hope, moving toward therapies that correct mutations at their genetic origin rather than managing their downstream consequences.

In summary, by employing mitochondrial base editors delivered via lipid nanoparticles and mRNA, scientists have charted a course toward effective, precise, and clinically viable mitochondrial DNA editing. This advance holds promise not only for rare genetic diseases but may also have far-reaching implications in tackling mitochondrial dysfunctions implicated in aging and cancer biology. Continued research and development in this arena are poised to unlock new frontiers in precision medicine.

As the field anticipates further experimental validation and eventual clinical trials, this discovery stands as a testament to the power of innovative genetic engineering. The convergence of molecular biology, bioengineering, and clinical science is paving the way for novel interventions capable of rewriting the mitochondrial genome, reshaping the landscape of genetic disease treatment forever.

Subject of Research: Cells

Article Title: Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors

News Publication Date: June 24, 2025

Web References: https://doi.org/10.1371/journal.pbio.3003207

References: Joore IP, Shehata S, Muffels I, Castro-Alpízar J, Jiménez-Curiel E, Nagyova E, et al. (2025) Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors. PLoS Biol 23(6): e3003207.

Image Credits: Martijn Koppens (CC-BY 4.0)

Keywords: mitochondrial diseases, base editing, mitochondrial DNA, DdCBE, lipid nanoparticles, mRNA delivery, gene therapy, mitochondrial mutations, patient-derived organoids, precision medicine, mitochondrial genome editing, mitochondrial pathology.